ESR1 and breast cancer: The CheckMate 7FL (NCT04109066) study aimed to investigate the benefit of adding nivolumab to neoadjuvant CT followed by adjuvant ET in patients with newly diagnosed early-stage high-risk ER+/HER2− BC.